Painful Nodules and Cords in Dupuytren Disease

Campe, Arndt von; Mende, Konrad; Omaren, H.; Meuli‐Simmen, Claudia

doi:10.1016/j.jhsa.2012.03.014

Cited by 28 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of the short MHQ has not yet been reported in outcomes studies for DD. Pain, which is included in both the DASH and MHQ, is seldom reported by people with DD [113] and may reduce the sensitivity of both tools.…”

Section: Discussionmentioning

confidence: 99%

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Ball

Pratt

Nanchahal

2013

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundDupuytren's disease of the hand is a common condition affecting the palmar fascia, resulting in progressive flexion deformities of the digits and hence limitation of hand function. The optimal treatment remains unclear as outcomes studies have used a variety of measures for assessment.MethodsA literature search was performed for all publications describing surgical treatment, percutaneous needle aponeurotomy or collagenase injection for primary or recurrent Dupuytren’s disease where outcomes had been monitored using functional measures.ResultsNinety-one studies met the inclusion criteria. Twenty-two studies reported outcomes using patient reported outcome measures (PROMs) ranging from validated questionnaires to self-reported measures for return to work and self-rated disability. The Disability of Arm, Shoulder and Hand (DASH) score was the most utilised patient-reported function measure (n=11). Patient satisfaction was reported by eighteen studies but no single method was used consistently. Range of movement was the most frequent physical measure and was reported in all 91 studies. However, the methods of measurement and reporting varied, with seventeen different techniques being used. Other physical measures included grip and pinch strength and sensibility, again with variations in measurement protocols. The mean follow-up time ranged from 2 weeks to 17 years.ConclusionsThere is little consistency in the reporting of outcomes for interventions in patients with Dupuytren’s disease, making it impossible to compare the efficacy of different treatment modalities. Although there are limitations to the existing generic patient reported outcomes measures, a combination of these together with a disease-specific questionnaire, and physical measures of active and passive individual joint Range of movement (ROM), grip and sensibility using standardised protocols should be used for future outcomes studies. As Dupuytren’s disease tends to recur following treatment as well as extend to involve other areas of the hand, follow-up times should be standardised and designed to capture both short and long term outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Ball

Pratt

Nanchahal

2013

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…In other cases of PN without trauma, growth of pre-existing Pacinian corpuscles can be due to unknown causes [7]. PN has been reported associated with glomus tumors or Dupuytren's disease [8]. Rare cases occurred in patients with neurofibromatosis type 1 [9].…”

Section: Discussionmentioning

confidence: 99%

Digital pacinian neuroma in a patient with myeloma

Soua¹,

Belhareth²,

Akkari³

2020

Our Dermatol Online

View full text Add to dashboard Cite

We present a case of Pacinian Neuroma (PN) associated with multiple myeloma (MM) in a 57-year-old man with a 6-month history of painful swelling of his fingers. Physical examination revealed definite palpable nodules and moderate swelling over the first phalanx of all his fingers. A biopsy confirmed the diagnosis of PN. The patient reported chronic back pain. Radiologically, a severe demineralization was found. MM was suspected. The results of complete blood count and biochemistry panels were within normal limits. Otherwise, immunoelectrophoresis demonstrated monoclonal light chains in blood and urine. Bone marrow biopsy was consistent with MM. The patient successfully underwent an autologous stem cell transplant with good response. A slight decrease in the size in PN was noted. To the best of our knowledge, no case of PN associated with MM had been reported. This occurrence may be accidental. However, further studies are required in order to explain this association.

show abstract

“…Darüber hinaus berichten Patienten über Brennen, Jucken, Druck-oder Spannungsgefühl. Die Erkrankung ist selten mit Schmerzen verbunden, allerdings kann es aufgrund der Knoten-und Strangbildung zu einer Druckschmerzhaftigkeit durch die Kompression des darunterliegenden sensiblen Nervs kommen [25].…”

Section: Symptome and Stadieneinteilungunclassified

Therapie der Dupuytren’schen Kontraktur mit Kollagenase

Girsch

Arora

Baur

et al. 2018

Handchir Mikrochir plast Chir

View full text Add to dashboard Cite

ZusammenfassungDie Dupuytren’sche Kontraktur (DK) oder Morbus Dupuytren ist eine progressive fibroproliferative Erkrankung des palmoplantaren Bindegewebes, bei der es zu einer charakteristischen Knoten- und/oder Strangbildung aus Kollagen kommt. Bei fortschreitender Erkrankung führt die Strangverdickung zu einer Beugekontraktur des betroffenen Fingers, die in einer deutlichen Behinderung der Betroffenen münden kann, insbesondere bei beidseitigem Befall.Die Erkrankung ist in Europa relativ verbreitet, wobei die Prävalenz in nordischen Ländern am höchsten ist. In Österreich geht man von rund 200 000 Betroffenen aus. Die Inzidenz steigt mit zunehmendem Alter, wobei Männer häufiger und früher erkranken als Frauen.Die Ätiologie der DK ist nicht vollständig geklärt, scheint jedoch multifaktoriell zu sein, wobei eine genetische Prädisposition als gesichert gilt. Der natürliche Verlauf der Erkrankung kann zwischen relativ gutartig und massiver Progredienz und Rezidivhäufigkeit variieren. Zumeist findet sich ein schubweiser Verlauf.Die DK ist nicht heilbar; die Behandlungsmethoden reichen von minimalinvasiven bis zu offenen chirurgischen Verfahren. Collagenase Clostridium histolyticum (CCH) ist eine nichtchirurgische, enzymatische Injektionsbehandlung für erwachsene Patienten (≥ 18 Jahre), die in Europa seit 2011 zur Behandlung der DK mit einem tastbaren Strang zugelassen ist. Klinische Studien und praktische Erfahrungen einzelner Zentren bestätigen die Wirksamkeit und Sicherheit der CCH-Behandlung von Beugekontrakturen.Das vorliegende Konsensus Statement wurde unter der Ägide der Österreichischen Gesellschaft für Handchirurgie und der Mitwirkung der Österreichischen Gesellschaften für Unfallchirurgie, Orthopädie und orthopädische Chirurgie sowie für Plastische, Ästhetische und Rekonstruktive Chirurgie erstellt. Es beschreibt die verschiedenen chirurgischen Verfahren unter besonderer Berücksichtigung der Kollagenase-Behandlung und stellt eine Orientierungshilfe für deren Einsatz dar. Das Statement soll nicht nur den Stand des Wissens der DK-Behandlung abbilden, sondern auch als Richtschnur dienen und zu einem einheitlich hohen Qualitätsstandard der Kontraktur-Behandlung in chirurgischen Zentren und spezialisierten Arztpraxen in ganz Österreich beitragen.

show abstract

Painful Nodules and Cords in Dupuytren Disease

Cited by 28 publications

References 12 publications

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice

Digital pacinian neuroma in a patient with myeloma

Therapie der Dupuytren’schen Kontraktur mit Kollagenase

Contact Info

Product

Resources

About